TrialJournal of cancer research and clinical oncology2022

GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients.

Lihua Yu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.